Inovio Pharmaceuticals, Inc.
INO
$1.34
$0.021.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -- | -- |
| Cost of Revenue | -25.44% | -12.56% | -20.37% | -28.83% | -37.11% |
| Gross Profit | 25.44% | 12.20% | 19.64% | 28.83% | 36.84% |
| SG&A Expenses | -8.93% | -12.69% | -5.07% | -8.55% | -16.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.32% | -12.61% | -14.69% | -22.44% | -30.67% |
| Operating Income | 19.32% | 12.38% | 14.20% | 22.44% | 30.46% |
| Income Before Tax | 74.44% | 0.06% | 119.43% | -80.79% | 27.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 74.44% | 0.06% | 119.43% | -80.79% | 27.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 74.44% | 0.06% | 119.43% | -80.79% | 27.04% |
| EBIT | 19.32% | 12.38% | 14.20% | 22.44% | 30.46% |
| EBITDA | 19.47% | 12.34% | 14.11% | 22.53% | 30.51% |
| EPS Basic | 87.83% | 44.16% | 109.39% | 2.48% | 48.90% |
| Normalized Basic EPS | 88.82% | 45.11% | 109.53% | 5.23% | 48.75% |
| EPS Diluted | 87.83% | 44.16% | 109.39% | 2.48% | 48.90% |
| Normalized Diluted EPS | 88.82% | 45.11% | 109.53% | 5.23% | 48.75% |
| Average Basic Shares Outstanding | 110.20% | 78.96% | 106.82% | 85.39% | 42.77% |
| Average Diluted Shares Outstanding | 110.20% | 78.96% | 106.82% | 85.39% | 42.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |